Fundraising Fox

Adcendo

3 known investors

Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs. The company translates scientific innovation into clinically differentiated medicines for patients with advanced solid tumors and other cancer types.

BiotechDigital HealthMedical Devices

Investors · 3

Vida Ventures✓ verifiedLos Angeles
Ysios CapitalBarcelona · $5.4M – $21.6M
Jeito Capitalreported · 2 sourcesParis

Funding

SEC filings, press & company announcements

$75M disclosed across 1 of 2 rounds · 2024–2026

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Adcendo Secures $75 Million Series C to Drive Lead ADC Programs Through Key Clinical Milestones - TipRanks.comtipranks.com · Apr 2026Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC1 Pipeline in Oncologybusinesswire.com · Apr 2026Adcendo Raises $75M Series C for ADC Pipeline - TAMradar Funding Rounds Signalstamradar.com · Apr 2026Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipelineprnewswire.com · Apr 2026Adcendo Raises $75M in Series C Fundingfinsmes.com · Apr 2026Adcendo raises $135m as ADC funding frenzy continues - Pharmaceutical Technologypharmaceutical-technology.com · Nov 2024

Frequently asked questions

What does Adcendo do?
Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs. The company translates scientific innovation into clinically differentiated medicines for patients with advanced solid tumors and other cancer types.
Who are Adcendo's investors?
Adcendo's investors include Vida Ventures, Ysios Capital, Jeito Capital.
How much funding has Adcendo raised?
Adcendo has disclosed $75M raised across 1 of its 2 known rounds.